Consensus statement on iron overload in myelodysplastic syndromes

被引：143
|
作者：
Bennett, John M. [1 ]
机构：
[1] Myelodysplast Syndromes Fdn, Crosswicks, NJ USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2008年 / 83卷 / 11期
关键词：
D O I：
10.1002/ajh.21269
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In May 2005 at the 8th International Symposium on Myelodysplastic Syndromes (MDS), a consensus meeting was held on iron overload in MDS (Seymour, Hematol Oncol Clin 2005; Suppl 1:18-25). The recommendations of the 2005 consensus meeting were discussed in the context of currently available evidence at the 9th International Symposium on Myelodysplastic Syndromes in Florence Italy, May 2007. The recommendations of the consensus working group are presented here. The recommendations are a continued refinement of the outcome of the 2005 consensus meeting and the ground-breaking work of others in this area (Seymour, Hematol Oncol Clin 2005; Suppl 1:18-25; Gattermann, Int J Hematol 2008;88:24-29; Alessandrino et al., Haematologica 2002;87:1286-1306; NCCN practice guidelines: Myelodysplastic Syndromes, version 2.2008). Am. J. Hematol. 83:858-861, 2008. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码：858 / 861
页数：4
相关论文
共 50 条
  • [31] Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes
    Roy, Noemi B. A.
    Myerson, Saul
    Schuh, Anna H.
    Bignell, Patricia
    Patel, Roger
    Wainscoat, Jim S.
    McGowan, Simon
    Marchi, Emanuele
    Atoyebi, Wale
    Littlewood, Tim
    Chacko, Joseph
    Vyas, Paresh
    Killick, Sally B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (04) : 521 - 524
  • [32] Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes
    González, FA
    Arrizabalaga, B
    Villegas, A
    Alonso, D
    Castro, M
    Remacha, A
    del Arco, A
    Núñez, GM
    MEDICINA CLINICA, 2005, 124 (17): : 645 - 647
  • [33] Mortality burden of transfusion dependency and iron overload in patients with myelodysplastic syndromes
    Arnan, M.
    Pomares, H.
    Esteban, L.
    Alonso, E.
    Pareja, L.
    Sanchez-Ortega, I.
    Fernandez de Sevilla, A.
    Ribes, J.
    Duarte, R. F.
    LEUKEMIA RESEARCH, 2013, 37 : S140 - S140
  • [34] Management of Transfusion-Related Iron Overload in Patients With Myelodysplastic Syndromes
    Shah, Jayshree
    Kurtin, Sandra E.
    Arnold, Louise
    Lindroos-Kolqvist, Petra
    Tinsley, Sara
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2012, 16 (03) : 37 - 46
  • [35] Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes
    Angelucci, Emanuele
    Cianciulli, Paolo
    Finelli, Carlo
    Mecucci, Cristina
    Voso, Maria Teresa
    Tura, Sante
    LEUKEMIA RESEARCH, 2017, 62 : 108 - 115
  • [36] Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Taher, Ali
    Kantarjian, Hagop M.
    ONCOLOGIST, 2009, 14 (05): : 489 - 496
  • [37] Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
    Gattermann, Norbert
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (01) : 24 - 29
  • [38] Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
    Norbert Gattermann
    International Journal of Hematology, 2008, 88 : 24 - 29
  • [39] Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy
    Shammo, Jamile M.
    Komrokji, Rami S.
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (07) : 577 - 586
  • [40] Labile plasma iron, more practical and more sensitive to iron overload in myelodysplastic syndromes
    Gu, Shucheng
    Xv, Yanjun
    Fei, Chengming
    Xiao, Chao
    Guo, Juan
    Zhao, Youshan
    Xv, Feng
    Li, Xiao
    Chang, Chunkang
    HEMATOLOGY, 2017, 22 (01) : 9 - 15
12345